International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

    April 2021 in “ Climacteric
    Sharon J. Parish, James A. Simon, Susan R. Davis, Annamaria Giraldi, Irwin Goldstein, S. Goldstein, Noel N. Kim, Sheryl A. Kingsberg, Abraham Morgentaler, Rossella E. Nappi, Kwangsung Park, Cynthia A. Stuenkel, Abdulmaged M. Traish, Linda Vignozzi
    TLDR Testosterone therapy is effective and safe for women with low sexual desire, but it's hard to access.
    The document highlighted that, as of 2021, there was substantial evidence supporting the safety, efficacy, and clinical use of systemic testosterone therapy for treating hypoactive sexual desire disorder (HSDD) in women. However, despite this evidence, access to testosterone therapy for women with HSDD remained a significant unmet need. This indicated a gap between the available scientific evidence and the practical accessibility of treatment options for affected women.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results